Personalised Hyperlipidaemia Therapies Guided by Pharmacogenomics - Trial NCT06217523
Access comprehensive clinical trial information for NCT06217523 through Pure Global AI's free database. This phase not specified trial is sponsored by National University of Singapore and is currently Not yet recruiting. The study focuses on Cardiovascular Diseases. Target enrollment is 700 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
National University of Singapore
Timeline & Enrollment
N/A
Apr 01, 2024
Dec 01, 2025
Primary Outcome
Changes in LDL-C, HDL-C, Total cholesterol, and Triglycerides,Change in creatine kinase,Incidence of myopathy complaints
Summary
This trial aims to evaluate the impact of clinical pharmacists' pharmacogenomics-guided
 choice and statin titration for managing hyperlipidaemia.
 
 The central hypotheses of this trial are (1) clinical pharmacists' pharmacogenomics-guided
 choice and titration of statins will lead to a more significant reduction in LDL-c; (2) lower
 incidence of myopathies with the use of statins for hyperlipidaemia management over 12 months
 compared to usual care by doctors alone. Active follow-up and titration should occur over the
 first six months. However, the participants will be followed up to 12 months to confirm the
 sustained LDL level attainment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06217523
Non-Device Trial